Thymoquinone chemically conjugated to doxorubicin: antitumor activity and subcellular localization

Q: What type of study is this?

This is a Experimental Study study.

Ismail Sami Mahmoud; Hamdi Nsairat; Shorouq Alsotari; Areej M. Jaber; Ezaldeen Esawi; Hiba Abdelnabi; Majed Al Holi; El Soubani Fatima; Walhan Alshaer; Fadwa Odeh

doi:10.1039/d5ra05492c

January 1, 2025RSC AdvancesOpen Access

Thymoquinone chemically conjugated to doxorubicin: antitumor activity and subcellular localization

View Full Paper

Ask AI

Bookmark

Share

Key Points

The hybrid drug thymoquinone-doxorubicin shows effective antitumor activity against cancer cell lines.
This study reveals that thymoquinone enhances doxorubicin's effectiveness, improving cancer treatment outcomes.
The drug's subcellular localization was characterized, suggesting targeted delivery to enhance its therapeutic effects.
Further preclinical work is needed to explore the full potential of this drug combination in diverse cancer types.

Implication

Hybrid thymoquinone-doxorubicin drug demonstrates antitumor activity in cancer cell lines, indicating effective cellular localization.

Abstract

A hybrid drug of thymoquinone (TQ)-doxorubicin (Dox) has been generated and characterized for cellular localization and anti-cancer activity in cancer cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mahmoud et al. (2025) studied this question.

synapsesocial.com/papers/68efa18f9d05deea71d13f96 https://doi.org/10.1039/d5ra05492c

View Full Paper

Ask AI

Bookmark

Share

Thymoquinone chemically conjugated to doxorubicin: antitumor activity and subcellular localization

Key Points

Implication

Abstract

Discussion

Cite This Study

Thymoquinone chemically conjugated to doxorubicin: antitumor activity and subcellular localization

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from RSC Advances

Keep reading

More related papers

More from RSC Advances